Detalles de la búsqueda
1.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A
; 116(2): 619-624, 2019 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30584090
2.
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Gynecol Oncol
; 149(3): 585-591, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29572027
3.
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Gynecol Oncol
; 147(1): 145-152, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28705408
4.
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.
Mol Cancer Ther
; 17(5): 1003-1011, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29440294
5.
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Clin Cancer Res
; 24(19): 4845-4853, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29941483
Resultados
1 -
5
de 5
1
Próxima >
>>